Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at Vasopressin.

Who Took Part

According to the abstract, 512 patients were involved.

By PubMed's age tags, the people studied were older adults, both men and women.

A total of 512 adult patients with in-hospital cardiac arrest were included between October 15, 2018, and January 21, 2021.

Patients were randomized to receive a combination of vasopressin and methylprednisolone (n = 245) or placebo (n = 267).

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Random assignment meant chance, not the researchers, decided who got Vasopressin and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vasopressin, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Vasopressin could be set against what happens without it.

More than one site took part, so the patients came from several places.

Multicenter, randomized, double-blind, placebo-controlled trial conducted at 10 hospitals in Denmark.

The last 90-day follow-up was on April 21, 2021.

What Was Measured

The subject headings attached to it are Cardiovascular Agents, Confidence Intervals, Denmark, Epinephrine, Glucocorticoids, Heart Arrest and Hyperglycemia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vasopressin in 512 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (JAMA), a journal based in United States.

More context: the Vasopressin compound page, all human trials.